Clinical trials with autologous adipose-derived stem cell (AdSC) therapy for ischemic heart diseases (IHDs) are ongoing. However, little is known about combinational therapeutic effect of AdSCs and statin poly(lactic-co-glycolic) acid (PLGA) nanoparticles on the ischemic myocardium. We investigated the hypothesis that statins, which have pleiotropic effects, augment the therapeutic potential of AdSCs and that AdSCs also act as drug delivery tools. Simvastatin-conjugated nanoparticles (SimNPs) significantly promoted migration activity without changing proliferation activity and upregulated growth factor gene expression in vitro. A small number of intravenously administered SimNP-loaded AdSCs (10,000 cells per mouse) improved cardiac function following myocardial infarction, inducing endogenous cardiac regeneration in the infarcted myocardium. The de novo regenerated myocardium was thought to be derived from epicardial cells, which were positive for Wilms' tumor protein 1 expression. These findings were attributed to the sustained, local simvastatin release from the recruited SimNP-loaded AdSCs in the infarcted myocardium rather than to the direct contribution of recruited AdSCs to tissue regeneration. SimNPloaded AdSCs may lead to a novel somatic stem cell therapy for IHDs. STEM CELLS TRANSLA- TIONAL MEDICINE 2019;8:1055-1067 
INTRODUCTION
Cardiovascular disease has been recognized as one of the major causes of death, and numerous patients suffer from heart failure, which is a leading cause for hospitalization worldwide [1] . Despite a variety of therapeutic options for preventing cardiovascular disease-induced heart failure, patients are often being treated with invasive cardiac surgery even at the end stage, including heart transplantation. In animal models of myocardial infarction (MI) and in early-phase clinical trials, bone marrow (BM)-derived stem/ progenitor cell transplantation has recently been reported to be effective as a new therapeutic strategy for promoting cardiomyogenesis and vasculogenesis in severe cardiovascular diseases. Among the variety of somatic stem cell candidates, that is, BM-/granulocyte-colony stimulating factor (G-CSF)-mobilized peripheral blood-derived endothelial progenitor cells (EPCs, CD34 + cells) [2] , umbilical cord blood-derived stem cells (CD133 + cells) [3] , and amnion-derived stem cells (mesenchymal stem cells, MSCs) [4, 5] , which have been studied for cardiac regenerative medicine, adipose-derived mesenchymal stem cells (AdSCs) are advantageous for therapeutic use not only because of their plasticity but also because a sufficient number of AdSCs can be easily collected by minimally invasive surgical techniques [6, 7] . AdSCs may have cardiac regenerative potential with their capability to differentiate into cardiomyocytes (CMs) in vitro [8] [9] [10] , and their ability to secrete angiogenic and antiapoptotic factors [11] may play a therapeutic role in the ischemic myocardium. Moreover, AdSCs have been reported to accumulate in the MI area, and thus, AdSCs are expected to serve as a cell source for cardiac regeneration [11] . However, the optimal therapeutic efficacy of AdSCs on ischemic heart diseases (IHDs) has been hindered by their poor survival and low differentiation rates of these cells in vivo [12] . Thus, a number of studies focused on improving the survival or differentiation rate of AdSCs into cardiovascular cells have been performed. Previous studies have indicated that ameliorating the cardiac milieu after an acute MI is crucial for the viability of transplanted AdSCs [13] and that directing AdSCs can facilitate their transdifferentiation potential in vivo [14] . Recently, we developed a novel controlled-release drug-conjugated nanoparticle that is formulated from the bioabsorbable PLGA polymer with hydrophobic drugs, and these nanoparticles were taken up by a variety of cells such as monocytes, vascular smooth muscle cells (VSMCs), and endothelial cells (ECs) [15] . In addition, compared with conventional drug delivery systems (DDSs), this nanoparticlemediated DDS significantly increased the therapeutic effects of ischemia-induced neovascularization in animal models [16] . Statins, a class of hydroxymethylglutaryl-coenzyme A reductase inhibitors, exhibit multiple biological activities such as promoting endothelial function, suppressing inflammation, stabilizing atherosclerotic plaques, reducing harmful oxidants, and, specifically, recruiting circulating EPCs for angiogenesis that are independent of their serum cholesterol-lowering effect [17, 18] . Therefore, we tested the hypothesis that AdSCs loaded with statin-conjugated PLGA nanoparticles exhibited a synergistic favorable effect on acute MI by promoting AdSC differentiation into cardiovascular cells and other biological effects. In this study, the combinational therapeutic effect of AdSCs and statin PLGA nanoparticles on the ischemic myocardium following MI was examined by histological and functional assessments in a mouse MI model.
MATERIALS AND METHODS

Adipose Tissue Harvesting and AdSC Isolation
Institutional Animal Care and Use Committee in Osaka Medical College approved all the following research protocols, including the surgical procedures and animal care. Human adipose-derived stem cells (hAdSCs) were isolated from the adipose tissue of adult patients, who gave informed consent, as surgical scraps from the surgical specimens of various surgeries. AdSCs were isolated from the adipose tissue as previously described with minor modifications [19] . Briefly, the adipose tissue was washed in phosphate buffered solution (PBS) and minced, followed by digestion in 5 ml of type I collagenase (1 mg/ml in 1% bovine serum albumin BSA/Hanks' balanced saline solution; Life Technologies Japan, Tokyo, Japan) for 30 minutes at 37 C with a rotator (Miltenyi Biotec K.K., Tokyo, Japan) according to the manufacturer's instructions. The digested tissue was filtered through a 40-μm cell strainer (BD Falcon, Tokyo, Japan) and centrifuged at 450g for 10 minutes. The cell pellet was suspended in 10% fetal bovine serum (FBS)/Dulbecco's modified Eagle medium (DMEM)/F12 medium and plated on culture dishes at 1,000-3,000 cells per cm 2 . After reaching 70% confluence, the attached cells were dissociated (0.25% trypsin EDTA; Invitrogen, Tokyo, Japan) and passaged as hAdSCs. The hAdSCs were used between the third and sixth passage in this study.
Cell Function Assay
The proliferation activity of hAdSCs was examined using a Cell Counting Kit-8 (Dojindo Laboratories, Kumamoto, Japan) according to the manufacturer's instructions. Briefly, hAdSCs were seeded onto 96-well culture plates at a density of 5 × 10 3 cells per well and were cultured in DMEM containing 10% FBS for 48 hours at 37 C with simvastatin-conjugated nanoparticles (SimNPs; 20 μg/ml, 50 μg/ml, 100 μg/ml). The optical density at the 450-nm wavelength was measured using a plate reader. The migration activity of hAdSCs was evaluated with a modified Boyden's chamber method as described previously [20] . Briefly, hAdSCs (5 × 10 4 cells per well) were seeded into the upper chambers of 24-well culture plates and the lower chambers were filled with DMEM/F12 medium containing 20% FBS with SimNPs (20 μg/ml, 50 μg/ml, 100 μg/ml), followed by incubation for 6 hours at 37 C. The migrated cells were stained with 4 0 ,6-diamidino-2-phenylindole (DAPI) and counted in four randomly selected high-power fields (HPFs; ×200, 0.15 mm 2 per HPF) per chamber under a fluorescence microscope' and the resulting numbers were averaged.
Fluorescence Immunocytochemistry for AdSC Differentiation Assays
The attached cells were fixed with 2% paraformaldehyde (PFA)/ PBS for 10 minutes at RT followed by washing in PBS and were permeabilized by incubating with 0.1% Triton X-100/PBS solution for 5 minutes at RT. The samples were blocked in 2% BSA/PBS antibody dilution buffer for 1 hour at RT. After removing the blocking solution, the following primary antibodies/ markers were added in antibody dilution buffer and incubated at 4 C overnight: anti-CD31 (1:100; Abcam, Cambridge, MA) and fluorescein-Griffonia simplicifolia lectin 1, and ILB4 (Vector Laboratories, Buringame, CA) were used for ECs; anti-SM22 (1:100; Abcam) and anti-Calponin (1:200; Abcam) antibodies were used to identify VSMCs; and GATA4 (Santa Cruz Biotechnology, Santa Cruz, CA) and cardiac Troponin T (Thermo Fisher Scientific, Fremont, CA) indicated CMs. After washing with PBS, the cells were incubated for 30 minutes at RT with the following secondary antibodies prepared at a 1:500 dilution in antibody dilution buffer: Alexa 488 donkey anti-goat IgG, Alexa 488 goat anti-rabbit IgG, and Alexa 488 goat anti-rat IgG (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA). After the secondary antibodies were removed and the cells were washed with PBS, nuclear counterstaining was performed by incubating the cells with DAPI solution (Sigma-Aldrich Japan K.K., Tokyo, Japan, 1 μg/ml in PBS) for 10 minutes at RT. The sample slides were covered by a coverslip and with mounting medium (ImmunoBioScience, Mukilteo, WA) followed by sealing with nail varnish before being evaluated under a fluo- The hAdSCs were seeded onto 6-well culture plates and cultivated for 24 hours at 37 C in DMEM containing 10% FBS medium with SimNPs (20 μg/ml, 50 μg/ml, 100 μg/ml). Cells were harvested; RNA was extracted with an RNeasy Mini kit (Qiagen, Tokyo, Japan); cDNA was synthesized using an ExScript RT kit (Takara, Siga, Japan); and amplification was performed on a Sequence Detection System 7000 (Applied Biosystem, Tokyo, Japan) according to the manufacturer's instructions. The primer sequences and GenBank accession numbers are as follows: vascular endothelial growth factor (VEGF, AB021221), forward TCTCCCTGATCGGTGACAGT and reverse GGGCAGAGCTGAGTGTTAGC; basic fibroblast growth factor (bFGF, J04513), forward CTCAGTCGGAAC AAATTGGAA and reverse GCCTGTCAGAGCCTGAAGAA; insulin-like growth factor-1 (IGF-1, X00173), forward CCATGTCCTCCTCGCATCTC and reverse CGTGGCAGAGCTGGTGAAG; angiopoietin-1 (Ang-1, D13628), forward GTTGGCAAGGTAGCAATACCA and reverse GCATAGTGGA TCAAGTCACCAA; stromal cell-derived factor-1 (L36033), forward TGAGAGCT CGCTTTGAGTGA and reverse GCCTCCATGGCATACATA GG; and glyceraldehyde-3-phosphate dehydrogenase (GAPDH, AF261085), forward CAGCCTCAAGATCATCAGCA and reverse TGTGGTCATGAGTCCTTCCA. The relative target gene mRNA expression was calculated with the comparative CT method. The amount of the target gene was normalized to that of the endogenous GAPDH control gene. The experiments were repeated in triplicate and the results were averaged.
Animals and Experimental Groups
Male nude mice (BALB/c nu/nu; CLEA Japan) aged 12 weeks were used in this study. For assessment of cardiac function by echo cardiography and histology, mice were assigned in the following groups (n = 8 in each group): the (a) PBS (control) group, (b) SimNP group, (c) NP-AdSC group, and (d) SimNP-AdSC group. The mice were euthanized for harvesting hearts at 28 days after MI induction. In control group, 100 μl of PBS was injected into the tail vein. In NP-AdSC group, nanoparticle (NP, 50 μg) loaded hAdSCs (1 × 10 4 /100 μl of PBS) were injected into the tail vein. In SimNP group, SimNP (50 μg) were injected into the tail vein. In SimNP-AdSC group, SimNP (50 μg) loaded AdSCs (1 × 10 4 /100 μl of PBS) were injected into the tail vein. All the four treatments were performed on day 3 following MI induction.
Since Wilms' tumor protein 1 (WT1)-positive cells were generally able to be detected only on day 3-5 following MI in ischemic myocardium, the mice were assigned in the above same four groups (n = 3 in each group) and were euthanized at 14 days after MI induction for sustained appearance of WT1-positive cells in ischemic myocardium by SimNP-AdSC administration. For assessment for final cardiac tissue regeneration following MI, the mice were assigned in the above same four groups (n = 3 in each group) and were euthanized at 56 days after MI induction.
Surgical Procedure
Male 12-to 16-week-old nude mice (BALB/c nu/nu; CLEA Japan) were anesthetized with intraperitoneal injections of 400 mg/kg 2,2,2-tribromoethanol (Avertin, Sigma-Aldrich Japan K.K., Tokyo, Japan). MI was induced by ligating the left anterior descending (LAD) coronary artery as described previously [20, 21] . Briefly, after the fourth to fifth intercostal space was opened, the heart was exteriorized and the pericardium was incised. Thereafter, the heart was held with the forceps, and MI was induced by ligating the LAD coronary artery with a 7-0 nylon suture precisely at the proximal site of the bifurcation of the diagonal branch. The predetermined hAdSCs (hAdSCtreated group) or control dose was transplanted 3 days after the MI induction.
Physiological Assessment of Left Ventricular Function
Cardiac function in the left ventricle (LV) was sequentially evaluated by echocardiography (Nemio 30, Toshiba Medical Systems, Tochigi, Japan) via changes in ejection fraction (ΔEF), fractional shortening (ΔFS), left ventricular end-systolic dimension (ΔLVDs), and left ventricular end-diastolic dimension (ΔLVDd) before MI induction and at 1 day and 2, 4, and 12 weeks afterward. The mice were sacrificed 4 weeks after MI surgery and the hearts were harvested for histological analysis. All procedures and analyses were performed by an experienced researcher who was blinded to the treatment assignments.
Histological Analysis
The hearts were removed from the euthanized animals 28 days after the MI and were retrogradely perfused with PBS, followed by 4% PFA through the right carotid artery. The hearts were fixed for 6 hours in 4% PFA and incubated overnight in a 15% sucrose solution. The tissues were embedded in OCT compound (Sakura FineTek, Japan) and sectioned at a 1 mm thickness for rats and at 0.5 mm thickness for mice, just below the LAD ligation level at 5 mm thickness as described previously. Masson's trichrome staining was performed to evaluate fibrotic sites. The extent of MI size was evaluated by calculating (a) the percentage of the entire cross-sectional LV area that was fibrotic, (b) the percentage of the fibrosis length out of the entire cross-sectional LV circumference, and (c) the percentage of the wall thickness out of the intact cross-sectional LV wall thickness using the NIH ImageJ 1.42 software and the Adobe Photoshop CS4 (Adobe Systems, San Jose, CA) software.
Immunohistochemistry
The MI-induced mouse hearts were harvested at predetermined time points after surgery and prepared for frozen tissue sectioning after fixation with 4% PFA/PBS. Double fluorescent immunostaining was performed to detect the transdifferentiation of the transplanted hAdSCs into ECs, with an antibody against human mitochondria antigen (hMitC, Abcam), into VSMCs, with antibodies again ILB4 (Vector Laboratories) and smooth muscle α-actin (Dako), or into CMs, with antibodies again cardiac troponin-I (Abcam), Nkx2.5, αMHC, and Gata4 (Abcam). Normal mouse IgG or PBS served as negative controls. The EC marker (biotinylated) ILB4 (1:100; Vector Laboratories) was used for capillary staining with a FITC-conjugated streptavidin-biotin binding method in mouse hearts. Antibodies against Ki67 (Abcam) and WT1 (Santa Cruz Biotechnology) were used as a marker for proliferating cells and embryogenesis-related proteins, respectively. Nuclei were counterstained with DAPI (Sigma), and sections were mounted in aqueous mounting medium. Images were examined using a fluorescence microscope (BZ-X700, Keyence, Osaka, Japan). The number of ILB4-positive capillaries within an HPF (×200) of the bilateral peri-infarct area was counted and averaged for the assessment of capillary density.
Statistical Analysis
All values are expressed as the mean AE SEM. Statistical analyses were performed using the Prism software program (GraphPad Software, CA). Nonparametric unpaired t tests (Mann-Whitney U test) were used for comparisons between two groups and repeated-measure two-way ANOVA with Bonferroni post hoc tests were used for comparing multiple groups. p values <.05 were considered statistically significant.
RESULTS
Proliferation and Migration Activities of hAdSCs and PLGA Nanoparticles Uptake in AdSCs
To clarify the advantage of the nanoparticle-mediated DDS with AdSCs, the cellular uptake and kinetics of the PLGA nanoparticles (NPs) were examined in cultured AdSCs. The cells were seeded in a 6-well culture dish and rhodamine-conjugated PLGA-NPs were added to the dish at different doses. After 1 or 2 hours of incubation, the extracellular rhodamine-conjugated NPs were washed out and the AdSCs were observed under a confocal laser microscope. AdSCs internalized PLGA-NPs after 1-and 2-hour incubations in culture, and the NPs were observed around the nuclei, indicating that the NPs were distributed in the cytosol (Fig. 1A) . Analysis of the in vitro statin release kinetics of the PLGA-NPs from AdSCs revealed an early burst of statin release, approximately 50% of the total simvastatin PLGA-NP uptake, on day 1, followed by the sustained release of the remaining PLGANPs for up to 2 weeks (Fig. 1B) . The migration activity of the cells treated with the different concentrations of PLGA-NP (50 μg/5 × 10 4 cells) or simvastatin NP (SimNP)-loaded AdSCs were evaluated using a Transwell culture plate, and the number of AdSCs that migrated toward the 20% fetal bovine serum (FBS) was determined as the migration activity. The AdSCs loaded with 50 μg of SimNPs/5 × 10 4 cells presented with significantly increased migration activity, whereas those loaded with 100 μg of SimNPs/5 × 10 4 cells had inhibited migration (Fig. 1C) . The proliferation activity of the AdSCs loaded with different concentrations of PLGA NPs or SimNPs was evaluated as the mean optical density value at a wavelength of 450 nm after 48 hours in culture. Although the proliferation activity of AdSCs loaded with 100 μg of SimNPs/5 × 10 4 cells was significantly reduced, when the control group was compared with the other groups with AdSCs loaded with different SimNP concentrations, no significant change in proliferation activity was observed (Fig. 1D) .
Simvastatin-Conjugated PLGA NPs Increased Growth Factor Gene Expression in AdSCs
Growth factor/cytokine production in AdSCs was evaluated as mRNA expression with quantitative real-time RT-PCR. VEGF A mRNA expression in AdSCs was significantly upregulated with the SimNP treatment, peaking at the concentration of 20 μg/5 × 10 4 cells (Fig. 1E) . VEGF C mRNA expression in AdSCs was significantly upregulated, peaking at an SimNP concentration of 100 μg/5 × 10 4 cells (Fig. 1F) FGF2 , Angiopoetin1, and IGF-1 mRNA expression levels in AdSCs were significantly upregulated with the SimNP treatment, peaking at the 50 μg/5 × 10 4 cells concentration (Fig. 1G-1I ). These results suggest that AdSCs have the ability to produce proangiogenic cytokines such as VEGF, FGF2, and Angiopoetin1 and to regulate the antiapoptotic growth factor IGF-1 in the acute phase following MI to promote neovascularization and inhibit cardiovascular cell death. Fig. 2A, 2C ). EC differentiation medium also significantly increased the percentage of ILB4/CD31-positive cells, and SimNP uptake further significantly increased this percentage (Fig. 2B, 2D ). However, under regular culture conditions, only a small population of AdSCs faintly expressed Calponin/SMα-actin, and these cells did not express ILB4/CD31. These results suggest that SimNP uptake enhanced the smooth muscle and endothelial differentiation of AdSCs under each differentiation condition.
Simvastatin-Conjugated NP-Loaded
AdSCs Exhibit High Differentiation Capacity for Vascular Cells Next, we assessed the transdifferentiation capacity of AdSCs with or without SimNPs using the markers Calponin/SMα-actin for VSMCs and Isolectin B4 (ILB4)/CD31 for ECs. SMC differentiation medium significantly increased the percentage of Calponin/SMα-actin-positive cells, and SimNP uptake further significantly increased this percentage (
SimNP-AdSC Transplantation Improved Cardiac Functional Recovery Following MI
Echocardiography assessment at 14 and 28 days after cell transplantation revealed that the left ventricular (LV) ejection fraction/LV fractional shortening parameters, which directly indicate LV contractile function, were significantly increased in the SimNP-AdSC-treated group than in the control-, NP-AdSC-, and SimNP-treated groups (Fig. 3A, 3B) , and the left ventricular dimension in diastole (LVDd)/left ventricular dimension in systole (LVDs) parameters, which indirectly indicate LV function, were significantly increased in the SimNP-AdSC-treated group than in the control-, NP-AdSC-, and SimNP-treated groups (Fig. 3C, 3D ). Next, we histologically assessed the effect of hAdSC transplantation with or without SimNPs on myocardial tissue regeneration. Representative Masson's trichrome staining images revealed that among all the groups, de novo muscle-like granulation tissue in the infarct zone was present only in the SimNP-AdSC group (Fig. 3E) . The damaged infarct zone myocardium was then examined quantitatively. Although the LV fibrosis area was not significantly reduced, the LV fibrosis length was significantly reduced and the wall thickness in the scarred area was significantly increased in the SimNP-AdSC group (Fig. 3F) . Fluorescence immunohistochemical analyses indicated that both ILB4-positive capillaries and SMα-actinpositive arteriole were frequently observed in the ischemic infarct area core site of the SimNP-AdSC-treated group only (Fig. 4A) and that the number of ILB4-positive capillaries (Fig. 4B ) was significantly increased in the ischemic border zone of the SimNP-AdSC-treated group (Fig. 4C) (Fig. 4D) . These results suggest that SimNP-AdSC transplantation preserved the global and regional LV function, with the reduced infarct size promoting neovascularization and inhibiting cell apoptosis in the ischemic myocardium after MI.
Recruited SimNP-AdSCs Induced Endogenous Cardiac Granulation Tissue Development in Infarcted Heart Tissue
First, at 3 days after cell infusion via the tail vein, we confirmed that human AdSCs (hAdSCs) were recruited to the ischemic myocardium. Double fluorescent detection for cardiac troponin-I (cTn-I), which is a marker for mature CMs (green), and rhodamine-conjugated PLGA NP-loaded hAdSCs (red) indicated that the systemically infused hAdSCs were recruited to the ischemic/damaged myocardium (Supporting Information Fig. S1 ). Next, to determine whether the recruited hAdSCs remained in the ischemic myocardium and transdifferentiated into CMs, we examined the hAdSCs by double immunofluorescence staining human mitochondria (hMitC) and cTn-I for CM. In the MI mice of the SimNP-AdSC (10,000 cells per mouse) group, no hMitC-positive cells were detected in the ischemic/damaged myocardium including in the de novo granulation tissue of the infarct area (data not shown). We then increased the number of SimNP-AdSCs for treatment to 50,000 cells per mouse and examined the MI heart sections 28 days following surgery to check if some SimNP-AdSCs remained in the ischemic/damaged myocardium. A small number of cTn-I and hMitC double-positive cells were observed in the de novo granulation tissue (Supporting Information Fig. S2A ), suggesting that a certain subpopulation of the transplanted SimNP-AdSCs survived and transdifferentiated into CMs in the ischemic myocardium. We further characterized the granulation tissue in the infarct scarred area of the SimNP-AdSC group. Nkx2.5 and Gata4, indicated in green, are markers of immature CMs, and cardiac α myosin heavy chain (αMHC) and cTn-I, indicated in red, are markers of mature CM (Fig. 5A and Supporting Information Fig. S2B ). On day 28 following the MI, a number of Nkx2.5-positive cells (Fig. 5A) and Gata4-positive cells (Supporting Information Fig. S2B ) were observed, whereas only a small number of αMHC-positive cells (Fig. 5A ) and cTn-I-positive cells (Supporting Information Fig. S2B) were observed in the same area of the newly developed granulation tissue. Interestingly, a number of Wilms' tumor protein 1 (WT1)-positive cells were frequently detected in the ischemic myocardium 14 days following MI. WT1, which is expressed in the myocardium only during the fetal period, is transiently expressed on days 3-5 after the MI in C57B6/J mice. Indeed, regardless of the mouse strain (BALB/c, BALB/c nu/nu, C57B6/J), we detected no WT1 expression on postinfarction day 14. However, numerous WT1-positive cells were observed in the epicardial site of the infarcted myocardium in the SimNP-AdSC group, even on postinfarction day 14 (Supporting Information Fig. S3 ). WT1/Ki67 double-positive cells were also detected in the epicardial site of the ischemic/damaged myocardium, suggesting that the WT1-positive, proliferating epicardium-derived cells developed granulation tissue and perhaps differentiated into CMs (Fig. 5B) .
Massive Myocardial Regeneration Was Induced by SimNP-AdSCs in the Scarred Infarct Area
Representative Masson's trichrome staining images revealed that even on day 56 following the MI, the PBS-treated heart still presented with a scarred infarcted myocardium. In contrast, in the SimNP-AdSC-treated heart, the scarred infarcted , and 28 days after the surgery were measured, and each parameter was analyzed statistically (*, p < .05; **, p < .01; ***, p < .001; and ***, p < .0001 vs. control, n = 8 in each group). Representative cardiac cross-sections of the infarcted myocardium at 28 days after surgery (E) in the control (phosphate buffered solution [PBS]) group, simvastatin-conjugated nanoparticle (SimNP; 10 μg) group, NP-adipose-derived stem cell (AdSC; 10 4 ) group, and SimNP-AdSC (10 μg/10myocardium with granulation tissue, which was observed on day 28 following MI, was largely replaced with regenerated de novo myocardium on day 56 (Fig. 6A) . The damaged infarct zone myocardium was then examined quantitatively. The LV fibrosis area and length were significantly reduced and the wall thickness in the scarred area was significantly increased in the SimNP-AdSC group (Fig. 6B) . The dramatic endogenous myocardial regeneration was also observed in another case in the SimNP-AdSC group (data not shown).
DISCUSSION
Marc Hedrick et al. were the first to isolate and identify adhesive pluripotent stem cells from adipose tissue in 2001 [22] , and since then, research on adipose-derived stem cells (AdSCs) has rapidly advanced. AdSCs have attracted attention for clinical applications since fat tissue can be harvested easily and safely, and AdSCs can also be isolated and compared with other cell sources such as BM-derived stem cells. AdSCs effectiveness has often been reported in MI animal models. Moreover, clinical trials have recently reported the safety and therapeutic effect of AdSCs on chronic myocardial ischemia and acute MI in Europe and the U.S. [23, 24] . However, a large number of AdSCs are required for a sufficient therapeutic effect. Considering these clinical applications, harvesting large numbers of cells from patients who are elderly or who have underlying diseases such as diabetes is often difficult and decreased cell-trophic effects have also been reported [25, 26] . For these reasons, the favorable outcomes of AdSC treatment alone may be limited. Thus, we were challenged to explore a novel strategy to increase the therapeutic potential of even a small number of AdSCs with "statins" for transplantation.
Statins are known to have pleiotropic effects in addition to their serum lipid-lowering ability and improve collateral circulation in the ischemic heart [27] and ischemic limbs [28, 29] in animal studies. However, these pro-angiogenic effects often require high daily systemic doses, which may lead to adverse effects in actual clinical practice. Therefore, we focused on bioabsorbable polymer (PLGA)-nanoparticles (NPs; PLGA-NPs) as an ideal material for local statin delivery and tested the hypothesis that the combination of statin-PLGA-NPs and AdSCs synergistically exhibit a favorable effect in a mouse model of MI. Improved cardiac function and a reduced infarct site area were observed only in the group treated with a combination of statin-loaded PLGA-NPs (SimNPs) and AdSCs. With SimNPs alone or with AdSCs combined with nondrug containing PLGANPs, no therapeutic effect was observed. The reason for the lack of therapeutic effect with the SimNPs alone was probably because the nanoparticles themselves did not sufficiently accumulate within the infarct site. Additionally, the combined AdSC and nondrug containing PLGA-NP treatment failed to activate cell function, and the number of cells was too small to achieve effectiveness with AdSCs alone. Following quick (within 
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1 hour) AdSC uptake of the statin-encapsulated PLGA-NPs, since the recruitment of transplanted AdSCs to ischemic myocardium would be also rapid, perhaps within a couple of hours, most of the loaded NPs will be still inside the AdSCs and significant amount of SimNPs would therefore be delivered to the ischemic myocardium. The recruited AdSCs released statin slowly along with intracellular PLGA hydrolysis and the statin promoted AdSC migration activity peaking at a dose of 50 μg/50,000 cells SimNP but inhibiting at a dose of 100 μg/50,000 cells SimNP. The inhibitory effect of SimNP at a dose of 100 μg/50,000 cells was attributed to over loading of PNGA-NPs on AdSCs or high dose of statin exposure to AdSCs, since high dose of statin is known to have an inhibitory effect on endothelial cell migration [30] . We detected the accumulation of rhodamine-labeled SimNPs in cardiac tissue (Supporting Information Fig. S1B ). We then speculate the reason why SimNP group demonstrated little therapeutic effect on myocardial tissue regeneration is because of insufficient concentration of simvastatin in local tissue. A systemically administered, small number of statin-PLGA-NP-loaded AdSCs were significantly recruited to the ischemic myocardium, and then, the statin was locally gradually released for cardiac tissue regeneration. AdSCs appear to play a role as a bio-DDS for sustained statin release at MI sites only (Supporting Information Fig. 4) . The sustained statin release from the recruited AdSCs might not only inhibit tissue inflammation [31] but also promote of circulating BM-derived stem/progenitor cell recruitment, contributing to enhanced angiogenesis in the ischemic myocardium [32] [33] [34] . Furthermore, locally released statin might activate WT1-positive, epicardium-derived cells [35] , and resident cardiac stem/progenitor cells and promote the transdifferentiation of these cells into CMs.
The therapeutic effect in our study was achieved with a smaller number of AdSCs than has ever been reported [19, 36] (Supporting Information Table S1 ). These functionally enhanced AdSCs with encapsulated statin-PLGA-NPs accumulated in the ischemic myocardium, and localized, sustained statin release from the AdSCs enhanced the effectiveness of epicardial cellderived myocardial tissue regeneration, since no AdSCs remained or were differentiated into vascular endothelial cells (ECs), vascular smooth muscle cells (VSMCs), and myocardial cells in the regenerated myocardium (data not shown). The effects of locally released-statins in SimNPAdSC group rather than the recruited AdSCs in NP-AdSC group appear to contribute to significant cardiac functional recovery with intrinsic myocardial tissue regeneration. This evolutionary technology may lead to the next generation of stem cell therapy not only for MI but also for other type of diseases, specifically inflammatory diseases. Indeed, we have already confirmed that this therapeutic strategy was fairly effective in autoimmune diseases such as interstitial pneumonia, scleroderma, and ulcerative colitis.
CONCLUSION
This unique method allows us to reduce the number of stem cells required for transplantation, allowing pulmonary thromboembolism to be avoided as a complication and reducing the amount of medicine may also avoid adverse side effects. Several promising features of this method exist: AdSC NP treatment (a) has a lowcost due to using somatic stem cells and the clinically available, established medicine statin; (b) is a quick and easy therapy due to the simple AdSC isolation procedure with rapid PLGA-NP uptake in AdSCs and the administration of intravenous drip infusions; and (c) sufficiently facilitates endogenous functional cardiac regeneration, which can avoid unnecessary/aggressive coronary interventional therapy or open-chest cardiac bypass surgery, resulting in a large reduction in medical expenses. We believe the practical use of this therapeutic strategy will provide relief for humans suffering from incurable diseases. An international patent application (PCT/JP2015/081329) aiming to clinically apply this technology has been filed, and a Japanese patent based on the PCT/JP2015/081329 patent application was issued in March 2017.
